Evaluation of the Safety and Performance of a Bioresorbable Nasal Dressing Containing Mometasone Furoate

Inclusion criteria

• Patient is 18 years or older
• Patient is scheduled to undergo bilateral endoscopic sinus surgery for Chronic Rhinosinusitis with nasal polyps (CRSwNP) or Chronic Rhinosinusitis without nasal polyps (CRSsNP)
• Patient is willing and able to comply with all study elements as indicated by their written informed consent
• Patients with a pre-operative Lund-MacKay score of ≥ 6.

Exclusion criteria

• Patient is pregnant or nursing
• Patients with a history of chronic epistaxis or experienced a significant epistaxis event (defined as epistaxis requiring medical intervention) in the past 3 months
• Patients with a platelet disorder
• Patients with a known or suspected allergy to device components
• Patients with known hemophilia
• Patients with insulin dependent diabetics
• Patients with an oral steroid dependent condition
• Patients with glaucoma, ocular hypertension, posterior subcapsular cataracts
• Patients with a (previous) diagnosis of Samter's Triad (aspirin-exacerbated respiratory disease (AERD))
• Patients that require nasal ointments or creams at time of device placement
• Patients with a neurological, medical, psychiatric condition, or social circumstance that would potentially increase risk, interfere with study participation, or confound interpretation of study data
• Patients with plans to (or otherwise anticipate the need to) undergo an ear, nose, throat (ENT) procedure within the 90 day study follow up
• Patients participating in another clinical research study (within 30 days prior to screening up till 90 days post-operative).
• Patients that used any form of corticosteroid or immunologics within 2 weeks prior to sinus surgery or during follow-up to day 30.